Effect of lisdexamfetamine on emotional network brain dysfunction in binge eating disorder

David E. Fleck, James C. Eliassen, Anna I. Guerdjikova, Nicole Mori, Stephanie Williams, Thomas J. Blom, Travis Beckwith, Maxwell J. Tallman, Caleb M. Adler, Melissa P. DelBello, Stephen M. Strakowski, Susan L. McElroy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We examined the effects of lisdexamfetamine (LDX) treatment on ventral prefrontal cortex (VPFC) and striatal brain activation in binge eating disorder (BED). We hypothesized that participants with BED have an abnormal brain response to palatable food cues, and that VPFC and striatal regions would respond to such cues after LDX treatment. Twenty women with moderate to severe BED consented to a 12-week, open-label trial of LDX with fMRI before and after treatment. Twenty obese women without BED served as healthy controls and received one fMRI. LDX was started at 30 mg/d with a target of 70 mg/d at week 12. At baseline, women with BED showed greater activation in ventrolateral prefrontal cortex (VLPFC), striatum, and globus pallidus to food pictures and brain activation to food pictures predicted clinical outcome at 12 weeks. After 12 weeks of LDX treatment, BED women showed significant reductions in globus pallidus activation. Reductions in ventromedial prefrontal cortex (VMPFC) and thalamus activation specifically correlated with binge eating and obsessive-compulsive symptom reductions, respectively. Results suggest that BED is characterized by an abnormally large VPFC-subcortical brain response to palatable foods that LDX treatment helps modify. Moreover, VPFC-subcortical activation at baseline is a potential biomarker of LDX response.

Original languageEnglish (US)
Pages (from-to)53-59
Number of pages7
JournalPsychiatry Research - Neuroimaging
Volume286
DOIs
StatePublished - Apr 30 2019

Fingerprint

Binge-Eating Disorder
Prefrontal Cortex
Brain
Corpus Striatum
Food
Globus Pallidus
Cues
Magnetic Resonance Imaging
Therapeutics
Bulimia
Lisdexamfetamine Dimesylate
Thalamus
Biomarkers

Keywords

  • Biomarker
  • FMRI
  • Functional magnetic resonance imaging
  • Prefrontal cortex
  • Striatum
  • Women

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Radiology Nuclear Medicine and imaging
  • Psychiatry and Mental health

Cite this

Fleck, D. E., Eliassen, J. C., Guerdjikova, A. I., Mori, N., Williams, S., Blom, T. J., ... McElroy, S. L. (2019). Effect of lisdexamfetamine on emotional network brain dysfunction in binge eating disorder. Psychiatry Research - Neuroimaging, 286, 53-59. https://doi.org/10.1016/j.pscychresns.2019.03.003

Effect of lisdexamfetamine on emotional network brain dysfunction in binge eating disorder. / Fleck, David E.; Eliassen, James C.; Guerdjikova, Anna I.; Mori, Nicole; Williams, Stephanie; Blom, Thomas J.; Beckwith, Travis; Tallman, Maxwell J.; Adler, Caleb M.; DelBello, Melissa P.; Strakowski, Stephen M.; McElroy, Susan L.

In: Psychiatry Research - Neuroimaging, Vol. 286, 30.04.2019, p. 53-59.

Research output: Contribution to journalArticle

Fleck, DE, Eliassen, JC, Guerdjikova, AI, Mori, N, Williams, S, Blom, TJ, Beckwith, T, Tallman, MJ, Adler, CM, DelBello, MP, Strakowski, SM & McElroy, SL 2019, 'Effect of lisdexamfetamine on emotional network brain dysfunction in binge eating disorder', Psychiatry Research - Neuroimaging, vol. 286, pp. 53-59. https://doi.org/10.1016/j.pscychresns.2019.03.003
Fleck, David E. ; Eliassen, James C. ; Guerdjikova, Anna I. ; Mori, Nicole ; Williams, Stephanie ; Blom, Thomas J. ; Beckwith, Travis ; Tallman, Maxwell J. ; Adler, Caleb M. ; DelBello, Melissa P. ; Strakowski, Stephen M. ; McElroy, Susan L. / Effect of lisdexamfetamine on emotional network brain dysfunction in binge eating disorder. In: Psychiatry Research - Neuroimaging. 2019 ; Vol. 286. pp. 53-59.
@article{f7f4a34844b045529108891d635ec034,
title = "Effect of lisdexamfetamine on emotional network brain dysfunction in binge eating disorder",
abstract = "We examined the effects of lisdexamfetamine (LDX) treatment on ventral prefrontal cortex (VPFC) and striatal brain activation in binge eating disorder (BED). We hypothesized that participants with BED have an abnormal brain response to palatable food cues, and that VPFC and striatal regions would respond to such cues after LDX treatment. Twenty women with moderate to severe BED consented to a 12-week, open-label trial of LDX with fMRI before and after treatment. Twenty obese women without BED served as healthy controls and received one fMRI. LDX was started at 30 mg/d with a target of 70 mg/d at week 12. At baseline, women with BED showed greater activation in ventrolateral prefrontal cortex (VLPFC), striatum, and globus pallidus to food pictures and brain activation to food pictures predicted clinical outcome at 12 weeks. After 12 weeks of LDX treatment, BED women showed significant reductions in globus pallidus activation. Reductions in ventromedial prefrontal cortex (VMPFC) and thalamus activation specifically correlated with binge eating and obsessive-compulsive symptom reductions, respectively. Results suggest that BED is characterized by an abnormally large VPFC-subcortical brain response to palatable foods that LDX treatment helps modify. Moreover, VPFC-subcortical activation at baseline is a potential biomarker of LDX response.",
keywords = "Biomarker, FMRI, Functional magnetic resonance imaging, Prefrontal cortex, Striatum, Women",
author = "Fleck, {David E.} and Eliassen, {James C.} and Guerdjikova, {Anna I.} and Nicole Mori and Stephanie Williams and Blom, {Thomas J.} and Travis Beckwith and Tallman, {Maxwell J.} and Adler, {Caleb M.} and DelBello, {Melissa P.} and Strakowski, {Stephen M.} and McElroy, {Susan L.}",
year = "2019",
month = "4",
day = "30",
doi = "10.1016/j.pscychresns.2019.03.003",
language = "English (US)",
volume = "286",
pages = "53--59",
journal = "Psychiatry Research - Neuroimaging",
issn = "0925-4927",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Effect of lisdexamfetamine on emotional network brain dysfunction in binge eating disorder

AU - Fleck, David E.

AU - Eliassen, James C.

AU - Guerdjikova, Anna I.

AU - Mori, Nicole

AU - Williams, Stephanie

AU - Blom, Thomas J.

AU - Beckwith, Travis

AU - Tallman, Maxwell J.

AU - Adler, Caleb M.

AU - DelBello, Melissa P.

AU - Strakowski, Stephen M.

AU - McElroy, Susan L.

PY - 2019/4/30

Y1 - 2019/4/30

N2 - We examined the effects of lisdexamfetamine (LDX) treatment on ventral prefrontal cortex (VPFC) and striatal brain activation in binge eating disorder (BED). We hypothesized that participants with BED have an abnormal brain response to palatable food cues, and that VPFC and striatal regions would respond to such cues after LDX treatment. Twenty women with moderate to severe BED consented to a 12-week, open-label trial of LDX with fMRI before and after treatment. Twenty obese women without BED served as healthy controls and received one fMRI. LDX was started at 30 mg/d with a target of 70 mg/d at week 12. At baseline, women with BED showed greater activation in ventrolateral prefrontal cortex (VLPFC), striatum, and globus pallidus to food pictures and brain activation to food pictures predicted clinical outcome at 12 weeks. After 12 weeks of LDX treatment, BED women showed significant reductions in globus pallidus activation. Reductions in ventromedial prefrontal cortex (VMPFC) and thalamus activation specifically correlated with binge eating and obsessive-compulsive symptom reductions, respectively. Results suggest that BED is characterized by an abnormally large VPFC-subcortical brain response to palatable foods that LDX treatment helps modify. Moreover, VPFC-subcortical activation at baseline is a potential biomarker of LDX response.

AB - We examined the effects of lisdexamfetamine (LDX) treatment on ventral prefrontal cortex (VPFC) and striatal brain activation in binge eating disorder (BED). We hypothesized that participants with BED have an abnormal brain response to palatable food cues, and that VPFC and striatal regions would respond to such cues after LDX treatment. Twenty women with moderate to severe BED consented to a 12-week, open-label trial of LDX with fMRI before and after treatment. Twenty obese women without BED served as healthy controls and received one fMRI. LDX was started at 30 mg/d with a target of 70 mg/d at week 12. At baseline, women with BED showed greater activation in ventrolateral prefrontal cortex (VLPFC), striatum, and globus pallidus to food pictures and brain activation to food pictures predicted clinical outcome at 12 weeks. After 12 weeks of LDX treatment, BED women showed significant reductions in globus pallidus activation. Reductions in ventromedial prefrontal cortex (VMPFC) and thalamus activation specifically correlated with binge eating and obsessive-compulsive symptom reductions, respectively. Results suggest that BED is characterized by an abnormally large VPFC-subcortical brain response to palatable foods that LDX treatment helps modify. Moreover, VPFC-subcortical activation at baseline is a potential biomarker of LDX response.

KW - Biomarker

KW - FMRI

KW - Functional magnetic resonance imaging

KW - Prefrontal cortex

KW - Striatum

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=85063102080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063102080&partnerID=8YFLogxK

U2 - 10.1016/j.pscychresns.2019.03.003

DO - 10.1016/j.pscychresns.2019.03.003

M3 - Article

C2 - 30903953

AN - SCOPUS:85063102080

VL - 286

SP - 53

EP - 59

JO - Psychiatry Research - Neuroimaging

JF - Psychiatry Research - Neuroimaging

SN - 0925-4927

ER -